Pulse Biosciences Reports Business Updates and Third Quarter 2023 Financial Results

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced financial results for the third quarter ended September 30, 2023. Recent Business Highlights Advanced feasibility and preclinical studies for the cardiac ablation clamp and catheter programs, and expect to file an FDA 510(k) submission for